{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-023505","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2023-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.817675+00:00","generated_at":"2026-06-14T16:59:49.835160+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cytokinetics reports positive Phase 2 data for aficamten in nHCM; Phase 3 to start 2H 2023","bullets":["At 10 weeks, aficamten improved KCCQ-CSS by 10.6 points (p<0.0001); 58% of patients had clinical symptom reduction.","56% of patients improved ≥1 NYHA class; 28% became asymptomatic (Class I) by Week 10.","Mean relative reductions: NT-proBNP 55% (p<0.0001) and high-sensitivity troponin I 21% (p<0.005).","In 14 patients with baseline angina, SAQ-AF score reduced 14.3 points (p=0.005), converting daily/weekly angina to weekly/monthly.","Aficamten well-tolerated; no discontinuations due to AEs, no LVEF<40%, and phase 3 trial planned for 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-023505","json":"https://secwatch.observer/filing/0000950170-23-023505.json","markdown":"https://secwatch.observer/filing/0000950170-23-023505.md","text":"https://secwatch.observer/filing/0000950170-23-023505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023023505/0000950170-23-023505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023023505/cytk-20230520.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T16:59:49.835160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}